HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hidetaka Noma Selected Research

Macular Edema

6/2022Intravitreal ranibizumab improves macular sensitivity in patients with central retinal vein occlusion and macula edema.
1/2022RELATIONSHIP BETWEEN CHOROIDAL FINDINGS AND GROWTH FACTORS, CYTOKINES, AND OTHER INFLAMMATORY MEDIATORS AFTER INTRAVITREAL RANIBIZUMAB INJECTION IN PATIENTS WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION.
12/2021The Impact of Interval between Recurrence and Reinjection in Anti-VEGF Therapy for Diabetic Macular Edema in Pro Re Nata Regimen.
9/2021Effects of ranibizumab on growth factors and mediators of inflammation in the aqueous humor of patients with diabetic macular edema.
3/2021Involvement of Cytokines in the Pathogenesis of Diabetic Macular Edema.
1/2021Change of cytokines after intravitreal ranibizumab in patients with recurrent branch retinal vein occlusion and macular edema.
1/2021Anti-VEGF Therapy Reduces Inflammation in Diabetic Macular Edema.
1/2021Retinal Blood Flow as a Predictor of Recurrence of Macular Edema after Intravitreal Ranibizumab Injection in Central Retinal Vein Occlusion.
12/2020Retinal Microcirculation and Cytokines as Predictors for Recurrence of Macular Edema after Intravitreal Ranibizumab Injection in Branch Retinal Vein Occlusion.
12/2020Intravitreal ranibizumab reduced ocular blood flow and aqueous cytokine levels and improved retinal morphology in patients with diabetic macular edema.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hidetaka Noma Research Topics

Disease

77Macular Edema
06/2022 - 01/2002
66Retinal Vein Occlusion
06/2022 - 08/2005
20Ischemia
10/2020 - 08/2005
14Inflammation (Inflammations)
01/2022 - 11/2006
14Cataract (Cataracts)
01/2019 - 01/2002
10Retinal Detachment (Retinal Detachments)
01/2021 - 09/2011
8Retinal Perforations
12/2016 - 06/2011
8Allergic Conjunctivitis (Giant Papillary Conjunctivitis)
08/2015 - 09/2009
8Diabetic Retinopathy (Retinopathy, Diabetic)
01/2014 - 08/2002
5Macular Degeneration (Age-Related Maculopathy)
01/2019 - 11/2013
5Hypertension (High Blood Pressure)
01/2019 - 08/2002
4Glaucoma
11/2013 - 04/2005
3Edema (Dropsy)
06/2022 - 01/2019
3Hypoxia (Hypoxemia)
03/2021 - 07/2010
3Hypersensitivity (Allergy)
03/2015 - 09/2009
2Neovascular Glaucoma
10/2020 - 01/2014
2Epiretinal Membrane (Epiretinal Membranes)
12/2016 - 03/2003
2Rhinitis
03/2015 - 12/2010
2Pruritus (Itching)
03/2015 - 12/2010
2Sneezing
03/2015 - 12/2010
2Nasal Obstruction
03/2015 - 12/2010
2Rhinorrhea
03/2015 - 12/2010
2Hyperlipidemias (Hyperlipidemia)
01/2014 - 11/2011
2Optic Neuritis (Retrobulbar Neuritis)
11/2013 - 11/2009
2Conjunctivitis
03/2011 - 12/2010
2Type 1 Diabetes Mellitus (Autoimmune Diabetes)
11/2005 - 06/2003
1Cerebral Infarction
03/2019
1Arteriosclerosis
01/2019
1Neuritis (Polyneuritis)
01/2017
1Anterior Uveitis
01/2017
1Immune Complex Diseases (Immune Complex Disease)
08/2015
1Exercise-Induced Allergies
03/2015
1Cerebrovascular Disorders (Cerebrovascular Occlusion)
01/2014
1Uveitis
11/2013
1Retinal Degeneration
11/2013
1Obesity
11/2013
1Metabolic Diseases (Metabolic Disease)
11/2013
1Neoplasms (Cancer)
11/2013

Drug/Important Bio-Agent (IBA)

56Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2022 - 01/2002
44Retinaldehyde (Retinal)IBA
03/2021 - 08/2005
24CytokinesIBA
01/2022 - 01/2005
15Ranibizumab (Lucentis)FDA Link
06/2022 - 01/2016
15Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
01/2021 - 05/2005
15Interleukin-6 (Interleukin 6)IBA
05/2014 - 01/2002
14Fluorescein (Funduscein)FDA LinkGeneric
05/2014 - 01/2006
11Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
01/2021 - 02/2013
10Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2022 - 10/2010
10pigment epithelium-derived factorIBA
04/2013 - 02/2006
8Triamcinolone Acetonide (Azmacort)FDA LinkGeneric
09/2016 - 01/2012
7Immunoglobulin E (IgE)IBA
03/2015 - 09/2009
7ImmunosorbentsIBA
01/2014 - 01/2002
7EnzymesIBA
01/2014 - 01/2002
5Bevacizumab (Avastin)FDA Link
09/2016 - 01/2013
5Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA
12/2013 - 06/2011
4InterleukinsIBA
01/2019 - 01/2009
4AllergensIBA
08/2015 - 09/2009
3SuspensionsIBA
01/2022 - 01/2017
3afliberceptIBA
11/2021 - 01/2017
3Indicators and Reagents (Reagents)IBA
01/2021 - 01/2017
3SteroidsIBA
01/2021 - 11/2006
3Monocyte Chemoattractant ProteinsIBA
01/2019 - 01/2014
3Adrenal Cortex Hormones (Corticosteroids)IBA
01/2017 - 08/2005
3Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA
01/2017 - 02/2013
3Proteins (Proteins, Gene)FDA Link
03/2015 - 01/2002
3PTX3 proteinIBA
02/2014 - 02/2013
3Latanoprost (Xalatan)FDA Link
01/2006 - 04/2005
2LigandsIBA
01/2018 - 06/2014
2Platelet-Derived Growth FactorIBA
01/2017 - 09/2016
2dorzolamide (Trusopt)FDA LinkGeneric
10/2005 - 04/2005
2brinzolamide (Azopt)FDA Link
10/2005 - 04/2005
2EndostatinsIBA
03/2003 - 08/2002
1Endothelial Growth FactorsIBA
01/2022
1N-acetyltryptophanamide (NATA)IBA
12/2021
1Inflammation MediatorsIBA
09/2021
1Growth Factor ReceptorsIBA
01/2019
1platelet-derived growth factor AIBA
01/2017
1Interleukin-8 (Interleukin 8)IBA
01/2017
1Diclofenac (SR 38)FDA LinkGeneric
12/2016
1Betamethasone (Celestone)FDA Link
12/2016
1Immunoglobulin G (IgG)IBA
08/2015
1AntibodiesIBA
08/2015
1Soaps (Soap)IBA
03/2015
1Lactic Acid (Lactate)FDA LinkGeneric
01/2014
1Cell Adhesion MoleculesIBA
01/2014
1Pyruvic Acid (Pyruvate)IBA
01/2014
1Adenosine Triphosphate (ATP)IBA
01/2014
1SirtuinsIBA
11/2013
1Sirtuin 1IBA
11/2013

Therapy/Procedure

19Vitrectomy
12/2016 - 06/2005
18Therapeutics
01/2022 - 04/2005
9Lasers (Laser)
12/2020 - 01/2006
8Intravitreal Injections
09/2016 - 01/2012
4Vitreoretinal Surgery
12/2016 - 06/2011
3Contact Lenses
03/2011 - 01/2010
2Intraocular Injections
10/2020 - 01/2019
2Light Coagulation
10/2020 - 01/2019
2Activities of Daily Living (ADL)
03/2015 - 12/2010
1Aftercare (After-Treatment)
06/2022
1Contraindications
03/2019
1Injections
09/2016